Tonix Pharmaceuticals Holding Corp (TNXP) Implied Volatility Current

Tracking TNXP implied volatility helps you identify when options premiums on Tonix Pharmaceuticals Holding Corp are historically cheap or expensive, and where the best trades are hiding. Tonix Pharmaceuticals Holding Corp implied volatility reflects the market's expectation of future price movement: when TNXP IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Tonix Pharmaceuticals Holding Corp's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For TNXP, tracking metrics like TNXP IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on TNXP signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases.

Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where TNXP implied volatility sits today versus where it has been. Our scanner ranks Tonix Pharmaceuticals Holding Corp implied volatility against its historical range, surfaces extremes in TNXP IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Tonix Pharmaceuticals Holding Corp IV is rich or cheap — measure it, then act on it.